pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Monoclonal Antibody · news · pharmadog
← back to Monoclonal Antibody
News · Monoclonal Antibody
333
stories
11d
‘We are proud to be in the lead’: Vaderis lands $152M for phase 3 study in rare blood vessel disorder
fiercebiotech
11d
Scholar Rock ditches Novo’s legacy Catalent plant in FDA refiling of SMA drug
fiercebiotech
11d
Opinion: We prepared for Ebola — but not this Ebola
stat
11d
Opinion: We prepared for Ebola — but not this Ebola
stat
11d
AbCellera women’s health data top ‘most aggressive upside scenario,’ putting Astellas and Bayer on notice
fiercebiotech
11d
Sobi pens $580M deal for Innate’s skin cancer drug ahead of phase 3 push
fiercebiotech
11d
Biogen’s targeted ALS treatment is reversing decline in some patients. Can more be helped?
biospace
14d
Third time’s the charm for Replimune as melanoma drug earns FDA greenlight
biospace
14d
FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma
fda press
15d
Sanofi pauses mid-stage lung study amid new CEO’s ‘rigorous portfolio prioritization’
biospace
15d
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
globenewswire health
15d
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
globenewswire health
15d
Context scraps bispecific T-cell engager program to extend cash runway deeper into 2027
fiercebiotech
15d
Narcan maker Emergent BioSolutions eliminates top R&D role in sweeping restructuring
fiercebiotech
15d
Attovia adds to biotech IPO momentum with $289M offering
biopharma dive
16d
Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
biopharma dive
16d
Sanofi suspends chronic lung disease phase 2 study, tied to ‘strategic business reasons’
fiercebiotech
16d
Gilead looks to upcoming inflammation, cancer catalysts as pressure to diversify mounts
biospace
16d
Amgen’s MariTide stands alone after obesity cull while analysts seek more M&A
biospace
16d
Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms
biospace
16d
5 NextGen winners who went public this year (and which ones are hiring)
biospace
16d
Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed data
fiercebiotech
16d
Merck plans trial of sac-TMT combo with Keytruda in lung cancer
endpoints
17d
Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss
biospace
17d
J&J pharma leader to retire; Krystal slumps on gene therapy miss
biopharma dive
17d
As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger
biospace
17d
Amgen drops early-stage obesity drug, upping pressure on MariTide
fiercebiotech
17d
Pathos inks back-to-back cancer contracts with AstraZeneca, China’s Alphamab
biospace
17d
Merck's anti-TL1A antibody scores a win in hidradenitis suppurativa, fails in SSc-ILD
endpoints
17d
Lisata lays off 72% of staffers, sues Kuva after planned merger falls apart
fiercebiotech
← prev
page 3 of 12
next →
